WO2020162441A9 - Granulomatous disease biomarker - Google Patents

Granulomatous disease biomarker Download PDF

Info

Publication number
WO2020162441A9
WO2020162441A9 PCT/JP2020/004074 JP2020004074W WO2020162441A9 WO 2020162441 A9 WO2020162441 A9 WO 2020162441A9 JP 2020004074 W JP2020004074 W JP 2020004074W WO 2020162441 A9 WO2020162441 A9 WO 2020162441A9
Authority
WO
WIPO (PCT)
Prior art keywords
granulomatous disease
biomarker
disease biomarker
sarcoidosis
subject
Prior art date
Application number
PCT/JP2020/004074
Other languages
French (fr)
Japanese (ja)
Other versions
WO2020162441A1 (en
Inventor
吉人 武田
淳 熊ノ郷
悠 二見
太郎 木庭
幸嗣 植田
Original Assignee
国立大学法人大阪大学
公益財団法人がん研究会
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人大阪大学, 公益財団法人がん研究会 filed Critical 国立大学法人大阪大学
Priority to JP2020571209A priority Critical patent/JPWO2020162441A1/ja
Publication of WO2020162441A1 publication Critical patent/WO2020162441A1/en
Publication of WO2020162441A9 publication Critical patent/WO2020162441A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention addresses the problem of providing a sarcoidosis biomarker and a method for using the biomarker. This problem is solved by a specific protein group in the extracellular vesicles in body fluid or a blood sample collected from a subject.
PCT/JP2020/004074 2019-02-04 2020-02-04 Granulomatous disease biomarker WO2020162441A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020571209A JPWO2020162441A1 (en) 2019-02-04 2020-02-04

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-017978 2019-02-04
JP2019017978 2019-02-04

Publications (2)

Publication Number Publication Date
WO2020162441A1 WO2020162441A1 (en) 2020-08-13
WO2020162441A9 true WO2020162441A9 (en) 2020-09-17

Family

ID=71947761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/004074 WO2020162441A1 (en) 2019-02-04 2020-02-04 Granulomatous disease biomarker

Country Status (2)

Country Link
JP (1) JPWO2020162441A1 (en)
WO (1) WO2020162441A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063102A1 (en) * 2009-11-19 2011-05-26 Celgene Corporation Apremilast for the treatment of sarcoidosis
WO2013155460A1 (en) * 2012-04-13 2013-10-17 Somalogic, Inc. Tuberculosis biomarkers and uses thereof
US9683999B2 (en) * 2014-01-07 2017-06-20 David R. Moller Diagnostic blood test for sarcoidosis
US10781489B2 (en) * 2015-03-04 2020-09-22 Wayne State University Systems and methods to diagnose sarcoidosis and identify markers of the condition
JP2020076572A (en) * 2017-03-14 2020-05-21 国立大学法人大阪大学 Tissue fibrosis biomarker

Also Published As

Publication number Publication date
WO2020162441A1 (en) 2020-08-13
JPWO2020162441A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
WO2019157214A3 (en) Deep learning-based diagnosis and referral of diseases and disorders
MX2009002522A (en) Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders.
MX2020006715A (en) Cd3-delta/epsilon heterodimer specific antibodies.
EP4253956A3 (en) Multi-organ "body on a chip" apparatus utilizing a common media
WO2016203053A3 (en) Methods of characterising cancer
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
MX2018012856A (en) Methods for determining dpp3 and therapeutic methods.
DE502006008028D1 (en) LIQUORDIAGNOSTIC IN VITRO METHOD FOR THE DIAGNOSIS OF DEMENTIA DISEASES AND NEUROINFLAMMATORY DISEASES
WO2018096375A3 (en) Determination of the receptive status of the endometrium
EP2672266A3 (en) Method for screening a lung transplant candidate for an elevated risk of rejection
WO2023129531A3 (en) Methods for diagnosing and/or treating alzheimer's disease
ATE272214T1 (en) METHOD FOR DIAGNOSIS OF SEPSIS UNDER SPECIFICATION OF S100B
WO2020162441A9 (en) Granulomatous disease biomarker
WO2011062782A3 (en) Innovative blood platelets biomarker for early diagnosis of alzheimer's disease
EP3716856A4 (en) Multi-modal ultrasound probe for calibration-free cuff-less evaluation of blood pressure
WO2020225799A3 (en) A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein
WO2019118906A3 (en) Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
RU2014135019A (en) Method for the diagnosis of choroid melanoma
SG11201901435UA (en) Monoclonal antibody against melk and utilization thereof
EP3976754A4 (en) Uses of patient-derived intestinal organoids for celiac disease diagnosis, screening and treatment
PL407244A1 (en) Electrochemical bio-sensor for detecting S100B protein
WO2020130838A3 (en) Antibodies for preventing or treating candidiasis
Argula et al. The differences between systemic sclerosis associated pulmonary arterial hypertension (ssc-Pah) and idiopathic pulmonary arterial hypertension (ipah): A quantitative lung morphometric analysis
EA201800225A2 (en) METHOD OF DIFFERENTIAL DIAGNOSTICS OF EARLY OR EXPRESSED STAGE OF RHEUMATOID ARTHRITIS WITH OSTEOARTHRITIS
Hernandez et al. Bmpr2 Loss-Of-Function leads to differential effects in lung fibrosis and pulmonary hypertension

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20752107

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020571209

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20752107

Country of ref document: EP

Kind code of ref document: A1